PPARG and cancer: However, some studies have reported that PPARγ agonists can also inhibit cell proliferation and induce differentiation in various cancer cell lines, such as human urothelial carcinoma [1],[4], rather than increasing cell proliferation as would be expected for a non-DNA reactive chemical's carcinogenic mode of action.